Key Takeaways
- Profit surged, guidance intact: Net profit rose over six-fold YoY, and management reaffirmed the full-year PAT guidance of INR1,000–1,200 crores, calling it comfortably achievable.
- December quarter flagged as weak: Q3 will be softer sequentially because the Kharif agro season is over and most remaining Lenalidomide volume for the calendar year has already been sold; a pickup is expected from March.
- Kothur FDA inspection is the live risk: The October inspection response was filed on November 8, starting a 90-day classification clock; management expects minimal impact because top products are already dual-sited, except for two Lenalidomide strengths representing ~7% of that franchise.
- Agro-business is scaling fast but still clearing old, high-cost inventory: Revenue is on track for INR150–160 crores this year, up from ~INR40 crores last year, with a target of INR200 crores next year; profitability is currently depressed by legacy inventory liquidation but is expected to improve sharply.
- What to watch next quarter: The FDA classification letter for Kothur, the actual depth of the Q3 dip, and any color on the pricing environment that will shape next year's growth.
Lenalidomide (Revlimid) Franchise
- Q3 volume already placed: Most of the remaining quantity for December has been sold, so the December quarter will not see the same contribution as September; sales resume from March.
- Market share trajectory: Management expects Natco's share of the innovator's total sale to increase over time, reaching almost one-third by the end of the term in late 2025.
- Competitive entry is priced in: When asked about Aurobindo entering the space, management said all competition is already factored into earnings projections and declined to quantify any specific impact.
- Revenue disclosure refused: Management declined to disclose Revlimid's percentage of total revenue or its current share of the innovator's sale, citing confidentiality.
Rajeev Nannapaneni: "It will increase my friend. It will increase... it will increase to almost -- by end of the term, it will increase to almost one third of the total sale of the innovator."
Kothur Plant: FDA Inspection & Mitigation
- Inspection timeline: The FDA inspected the Kothur plant in October; Natco submitted its response, rectification and remediation plan on November 8, which starts the 90-day period for the agency to issue a classification.
- Dual-site strategy limits exposure: All of the top 5–6 revenue products already have approvals from the Vizag site in addition to Hyderabad/Kothur, a deliberate strategy ingrained over the last five to six years.
- The uncovered tail: Lenalidomide 2.5 mg and 20 mg strengths, which together account for about 7% of total Lenalidomide revenue, currently lack Vizag approval; batches are on stability under a procedure called CB30, and if 90-day stability data is satisfactory, even those can be moved.
- Management stance: The company expects minimal overall impact but is waiting for the classification before making any decisions.
Rajeev Nannapaneni: "Overall, I think our impact will be minimal. So I think let's wait for the classification of the inspection and we'll make a decision."
Agro-Business: Scaling With Margin Drag
- Revenue ramp: The division has grown from near-zero to ~INR40 crores last year, an expected INR150–160 crores this year, and a minimum target of INR200 crores next year, with a compounded growth ambition of another 25% the following year.
- Profitability temporarily suppressed: Current profits are low because the company is clearing high-cost inventory that was procured in earlier years and could not be sold for a long time; raw material costing has since improved with a diversified supplier base.
- Pipeline building: Management expects at least 2–3 unique products in the next 12–18 months and a very good profit run next year.
- Seasonality note: The agro business contributes to the Q3 softness because the Kharif season is over.
Other Business Segments
| Segment | Trend | Commentary |
|---|---|---|
| Non-US formulations (Brazil, Canada) | ▲ Strong growth | Doing extremely well; expected to grow another 25% a year; some approvals pending in the next 1–1.5 years with benefit visible in FY25. |
| Domestic formulations | ▬ Stable | Half-year growth around 10–12%; organic growth expectation ~8–10%; the missing piece is an acquisition, held up by valuation discussions. |
| Dash Pharmaceuticals (US subsidiary) | ▼ Loss-making | Launched some older products and doing reasonably well, but still losing money in its early stage; management expects it will take at least 1.5–2 years before it turns. |
| Semaglutide (with Viatris) | ▬ Early stage | Filed from a CMO site for both Ozempic and Wegovy; review and patent litigation are in very early days; no timeline can be given. |
- No participation in Victoza or Saxenda: Natco has no filing on Victoza and has not disclosed anything on Saxenda.
- Humira: Not in Natco's pipeline.
- R&D and FTF filings: The company is working on another two or three first-to-file opportunities in the initial stage; filings are expected in FY25, with nothing in the next four to five months.
Rajeev Nannapaneni: "I just found it to be very premature to give a timeline. I would refrain from doing that. Once it develops, I think we will give you some time to come. As of now, it's too premature."
Margins, Cash & Capital Allocation
- Margin drivers this quarter: Good product launches, a strong agro-business quarter, and the Revlimid contribution all combined to lift margins.
- Q3 margin reset: Current-quarter EBITDA will not be sustained in Q3 because of the seasonal and product-timing factors already noted; margins are expected to pick up again starting from March.
- Medium-term confidence: Management expects margins to sustain for at least the next couple of years based on the pipeline.
- Cash position: Cash has improved dramatically and is expected to increase further by year-end; India cash is held in fixed deposits with banks and financial institutions, offshore cash in dollar deposits.
- Capital allocation philosophy: The company's stated job is to invest in pharmaceutical research, manufacturing and acquisitions, not equity market investments; a buyback has already reduced equity by about 2%.
- Inorganic growth: The company is looking at opportunities and opening subsidiaries in multiple countries, supported by the improved cash position.
Rajeev Nannapaneni: "Our job is not to do equity stock market investment. Our job is to invest in pharmaceutical research and pharmaceutical manufacturing and pharmaceutical acquisition."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year PAT guidance | INR1,000–1,200 crores; "no problem achieving it" | FY24 |
| Q3 sequential weakness | December quarter will not be as strong as September; agro season over, Revlimid sale not there | Q3 FY24 |
| Q4 pickup | Things will pick up again for the March quarter | Q4 FY24 |
| Agro-business revenue | INR150–200 crores this year; minimum INR200 crores next year; 25% compounded growth targeted thereafter | FY24 / FY25 |
| Agro-business profitability | Expectation of a very good profit run in the next year | FY25 |
| Non-US geography growth | Brazil and Canada expected to grow another 25% a year | Ongoing |
| Non-US approvals benefit | Some approvals pending; benefit visible in FY25, nothing before March 2024 | FY25 |
| FTF filings | Another 2–3 products in initial stage; filings in FY25, nothing in next 4–5 months | FY25 |
| Dash Pharmaceuticals turnaround | Will take at least 1.5–2 years before it turns | FY26–FY27 |
| Lenalidomide market share | Will increase to almost one-third of innovator's total sale by end of term | End of 2025 |
| Margin sustainability | Expect margins to sustain for at least the next couple of years based on pipeline | FY25–FY26 |
| Kothur FDA classification | 90-day clock started from November 8 response submission | By ~February 2024 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Consolidated total revenue | ₹1,060.8 cr, growth of roughly 134% YoY vs ₹452.6 cr |
| Consolidated net profit | ₹369 cr, over six-fold increase YoY vs ₹56.8 cr |
| PAT guidance for FY24 | ₹1,000 cr to ₹1,200 cr |
| Brazil revenue | ₹34 cr in the quarter |
| Canada revenue | ₹60 cr to ₹61 cr in the quarter |
| Agro-business revenue | ₹150 cr to ₹160 cr expected this year, minimum to ₹200 cr; last year about ₹40 cr |
| Agro-business seasonal split | 60% Kharif, 40% Rabi |
| Domestic business growth | 10% to 12% half-year growth |
| Domestic organic growth expectation | 8% to 10% |
| R&D spend | 8% to 10% of revenue |
| Net cash level | ₹1,550 cr as of October 31; cash and equivalents ₹1,657 cr, foreign bill discounting borrowing ₹108 cr |
| Average yield on India rupee deposits | 7.5% to 7.75% |
| Cash return in offshore subsidiaries | 5% to 5.5% |
| Equity exposure | 5% to 6% of total cash exposure |
| Revlimid volume share by end of term | one third of innovator's total sale, term ends by 2025 end |